Immune cell therapy GT201 targets advanced tumors in early trial

NCT ID NCT06144671

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, not cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The fifth medical center of the General Hospital of the Chinese people's Liberation Army

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Union Hospital Tongji Medical College Huazhong University Of Science And Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • West China Hospital Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••